FierceBiotechOriginal article
{"a":[{"_":"Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay","$":{"href":"/medtech/eckman-coulter-grows-alzheimers-dx-portfolio-ce-mark-new-assay","hreflang":"en"}}]}
RegulatoryapprovedAccess p-Tau217 assayPositive
AI Analysis
Summary
Beckman Coulter obtained CE mark approval in Europe for its Access p-Tau217 assay, expanding its Alzheimer's disease diagnostic portfolio.
Outcome Details
CE mark approval in Europe
Importance:5/10
Sentiment:
0.60
diagnosticsAlzheimer's diseaseCE markEuropeportfolio expansion
Read the original article
Published by FierceBiotech on July 7, 2026 7:57 AM
